Novartis AG is keeping quiet when it comes to specific sales of its gene therapy Zolgensma but CEO Vas Narasimhan has said that contrary to some analyst claims, the launch is going well.
There is huge interest in Zolgensma (onasemnogene abeparvovec), which was approved in the US for all three types of spinal...